Oral GLP-1 Pills Are Here: What's Actually Available Now

If you have been waiting for a GLP-1 you can take as a pill instead of an injection, the wait is over. As of mid-2026, two GLP-1 pills are FDA-approved for weight management and sitting on pharmacy shelves: oral Wegovy (semaglutide), approved in December 2025, and Foundayo (orforglipron), Eli Lilly's once-daily tablet, approved in April 2026. A third oral GLP-1, Rybelsus, has been around since 2019 but is a diabetes drug, not a weight-loss one. The pills work nearly as well as injectable semaglutide, though the strongest injection — tirzepatide — still loses more weight. Here is the honest picture.

The Pills You Can Actually Get Right Now

Let's start with what's real and buyable, because a lot of the coverage still frames oral GLP-1s as a future arrival. They aren't. Three oral GLP-1s are FDA-approved and on the U.S. market today — two of them for weight management.

Oral Wegovy (semaglutide 25 mg) — the first weight-loss pill

Oral Wegovy was the one that broke the seal. The FDA approved it for chronic weight management on December 22, 2025, and it reached pharmacies in January 2026. It is the same molecule as injectable Wegovy — semaglutide — reformulated into a daily tablet using an absorption enhancer called SNAC that helps the drug survive your stomach. In the OASIS 4 trial, people on the 25 mg dose lost an average of 13.6% of their body weight over 64 weeks, close to what the injection delivers. The catch is the routine: you take it first thing in the morning on an empty stomach with no more than four ounces of plain water, then wait 30 minutes before eating or drinking anything else. We cover this pill in depth on our complete oral Wegovy guide.

Foundayo (orforglipron) — Eli Lilly's once-daily pill

Foundayo is the newer arrival and, in one important way, the more convenient one. The FDA approved it for adults with obesity, or overweight plus a weight-related condition, on April 1, 2026. It reached LillyDirect and telehealth the same day and rolled out to U.S. retail pharmacies within about a week. Unlike oral Wegovy, Foundayo is a non-peptide small molecule — it doesn't need the SNAC trick to be absorbed, which means you can take it any time of day, with or without food or water. No morning fasting window. In the Phase 3 ATTAIN-1 trial, adults on the highest dose lost an average of 12.4% of their body weight (about 27 pounds) over 72 weeks, versus roughly 0.9% on placebo. It comes in six tablet strengths (0.8 mg up to 17.2 mg) that you step up gradually.

Rybelsus (oral semaglutide 3-14 mg) — a pill, but for diabetes

Rybelsus is worth naming because it causes real confusion. It is an oral semaglutide tablet from Novo Nordisk that has been available since September 2019 — so technically there has been a GLP-1 pill for years. But Rybelsus is FDA-approved only for type 2 diabetes, at doses of 3, 7, and 14 mg, and in 2025 it also picked up an indication to reduce cardiovascular risk in adults with type 2 diabetes. It is not approved for weight loss, and its top dose (14 mg) is well below the 25 mg weight-management dose of oral Wegovy. If you have seen someone lose weight "on Rybelsus," that was an off-label effect of a diabetes drug, not a weight-loss approval.

How the Pills Compare to Each Other

The practical split is simple. Between the two weight-loss pills, oral Wegovy has the slightly higher trial weight-loss figure and a longer real-world track record; Foundayo has the friendlier daily routine because there is no fasting window. Neither is clearly "the winner" — they haven't been compared head-to-head at their approved doses — so for most people the deciding factors are convenience, cost, and what a prescriber recommends.

Do the Pills Work as Well as the Shots?

This is the question that matters most, so here is the plain answer: the best pills are close to injectable semaglutide, but the strongest injection still wins. It helps to line the trial averages up side by side, keeping in mind these come from separate studies rather than one head-to-head trial.

So the ranking, roughly, goes: tirzepatide injection at the top, then injectable semaglutide, then the two pills a step below. That gap is real, but so is the perspective. A 12-13% average weight loss from a pill is dramatically more than lifestyle change alone typically delivers, and for many people the difference between a weekly needle and a daily tablet is the difference between starting a medication and never starting one. The best treatment is the one you will actually take. If maximum weight loss is your single priority, the injections — especially tirzepatide — still lead; our Zepbound vs Wegovy comparison breaks down the injectable side.

What the Pills Cost

We won't pretend the price isn't the scariest part — it is for most people. The good news is that both weight-loss pills launched at roughly the same, relatively accessible entry point, well below the four-figure list prices that made GLP-1s a national story.

• Oral Wegovy: about $149/month for starter doses through a temporary Novo Nordisk self-pay window, with commercial-insurance copays commonly landing at $0-$25/month.
• Foundayo: starts at $149/month for the lowest dose through LillyDirect self-pay, and can be as little as $25/month with commercial insurance plus the manufacturer savings card.
• Rybelsus: priced as a diabetes drug; coverage varies, and it is not the relevant option if weight loss is your goal.

There is also a Medicare angle worth knowing, and both pills have one. Per Eli Lilly's launch materials, eligible Medicare Part D patients who meet the clinical criteria may be able to get Foundayo (orforglipron) for as little as $50 a month beginning July 1, 2026. Oral Wegovy — which is semaglutide, a different drug made by Novo Nordisk — has its own separate Medicare Part D savings pathway on a similar timeline. For the full landscape of what these medications cost and every way to pay less, see our Wegovy cost breakdown and our deeper 2026 guide to the real monthly cost of GLP-1s.

Who a Pill Actually Makes Sense For

A pill is not automatically the "better" choice — it is a different set of trade-offs. It tends to make sense if:

• You are needle-averse. This is the big one. For a lot of people, a weekly injection is the single barrier to starting, and swapping it for a tablet removes that wall entirely.
• You travel or lack reliable refrigeration. The pills don't need to be kept cold the way injectable pens do, which makes them simpler to carry.
• You want the simplest possible daily routine. Here Foundayo has a specific edge — no food-timing rules at all — while oral Wegovy asks for a morning fasting window.

A pill makes less sense if your top priority is the largest possible weight loss, since the strongest injection (tirzepatide) still outperforms every pill on the market, or if you prefer a once-weekly rhythm over remembering something daily. None of this is a prescription — it is the set of questions worth bringing to a provider. If you are not sure where to start, our 2-minute quiz can point you toward the right questions, and our provider reviews compare the telehealth programs that prescribe these options.

What's Still in Trials (Correctly Attributed)

The oral GLP-1 field is about to get more crowded, but it is worth being precise about who is making what — the news coverage frequently mixes these up.

Elecoglipron (AZD5004) — AstraZeneca

Elecoglipron is AstraZeneca's once-daily oral small-molecule GLP-1. In the Phase 2 VISTA trial, adults with obesity or overweight plus a weight-related condition lost an average of 10.5% of their body weight over 26 weeks on the 75 mg dose, versus 0.6% on placebo. Those results were published in The Lancet and presented at the American Diabetes Association meeting in June 2026, and AstraZeneca has said the drug is advancing into a Phase 3 program. It is not approved yet, and it is not an Eli Lilly drug — a distinction the original round of coverage often got wrong.

Danuglipron — Pfizer (discontinued)

You may still see danuglipron listed as an upcoming oral GLP-1. It isn't. Pfizer discontinued danuglipron for weight management in April 2025 after a single trial participant developed signs of a possible drug-induced liver injury, which resolved once they stopped the drug. Pfizer had already dropped a twice-daily version in 2023 over tolerability. Danuglipron is no longer in active development, so it is not a pill you will be able to get.

Others on the horizon

Novo Nordisk and other companies have next-generation oral candidates in earlier development, including molecules that combine GLP-1 with other gut hormones. These are genuinely promising but still years from any approval, and none should be counted on as a near-term option today. We cover the pipeline that is actually maturing in our oral Wegovy guide.

Honest Caveats

A few things the marketing tends to skip:

• The side effects are the same family. Pills are still GLP-1s, so nausea, constipation, diarrhea, and vomiting — especially while stepping up the dose — are common. A tablet doesn't spare you the gut effects. Our side effects guide covers what's normal and what isn't.
• Daily beats weekly for forgetting. A once-weekly injection is one decision a week; a daily pill is seven. Adherence matters, and oral Wegovy's morning fasting rule adds friction some people find hard to keep up.
• Regain is still on the table. Like the injections, these are treatments for an ongoing condition, not a cure. Weight tends to return after stopping, which is worth planning for before you start — see what happens when you stop a GLP-1.
• Prices and coverage are unstable. The $149 and $25 figures above reflect launch-period self-pay and savings-card terms that can change. Verify the live number before committing.

The Bottom Line

Oral GLP-1s are no longer a promise — they are prescriptions you can fill this week. Oral Wegovy and Foundayo are both FDA-approved for weight loss and both start around $149/month, with Foundayo offering the more forgiving daily routine and oral Wegovy the slightly higher trial weight-loss number. Rybelsus is a pill too, but a diabetes one. The pills work nearly as well as injectable semaglutide and clearly beat doing nothing, though tirzepatide's injection still tops them all. And if you have been reading that "elecoglipron from Eli Lilly" or "Pfizer's danuglipron" are coming soon — the first is AstraZeneca's and still in trials, and the second was discontinued in 2025. For anyone who has put off a GLP-1 because of the needle, there is now a real, approved, swallowable option to raise with a provider.

Related Articles

• Oral Wegovy: The First GLP-1 Weight Loss Pill (Full Guide)
• How Much Does Wegovy Cost? Every Path Compared
• The Real Monthly Cost of GLP-1s in 2026
• Zepbound vs Wegovy: Which Injection Loses More Weight?

References

• Eli Lilly and Company. "FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions." Investor news release, April 1, 2026. investor.lilly.com — Foundayo/orforglipron approval date, manufacturer, indication, and once-daily no-restriction dosing.
• Eli Lilly and Company. "Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S." Press release, April 2026. prnewswire.com — $149/month self-pay starting price, $25/month with commercial insurance and savings card, six tablet strengths (0.8-17.2 mg), retail availability date.
• Eli Lilly and Company. "What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management." 2026. investor.lilly.com — Eligible Medicare Part D patients may access Foundayo (orforglipron) for $50/month beginning July 1, 2026 (through Dec 31, 2027) if clinical criteria are met.
• Drugs.com. "Foundayo (orforglipron) FDA Approval History." 2026. drugs.com — Confirms April 1, 2026 approval and second oral GLP-1 for weight management after oral Wegovy.
• Aronne LJ, et al. / Eli Lilly. ATTAIN-1 Phase 3 trial of orforglipron. 2026. Reported via AJMC — Highest-dose orforglipron ~12.4% (~27.3 lb) average weight loss over 72 weeks vs ~0.9% placebo.
• Novo Nordisk. "FDA approves oral Wegovy (semaglutide 25 mg)." Oral Wegovy approval, December 22, 2025; OASIS 4 trial. Summarized on our oral Wegovy guide — ~13.6% average weight loss over 64 weeks; $149/month starter self-pay pricing; empty-stomach dosing.
• Novo Nordisk. "FDA approves Rybelsus (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes." September 2019. prnewswire.com — Rybelsus type 2 diabetes indication and 3/7/14 mg doses; 2025 CV risk-reduction label update.
• Wharton S, et al. "Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial." The Lancet, 2026. PMID: 42259337. pubmed.ncbi.nlm.nih.gov — AstraZeneca's elecoglipron (AZD5004); ~10.5% weight loss at 26 weeks on 75 mg vs 0.6% placebo.
• AstraZeneca. "Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme." Press release, 2026. astrazeneca.com — Confirms AstraZeneca as the maker and advancement into Phase 3 (EMBOLD/ELUMINATE).
• Pfizer. "Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron." April 14, 2025. pfizer.com — Discontinuation of danuglipron for chronic weight management after a drug-induced liver-injury signal.
• Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 384(11):989-1002. — STEP 1: injectable semaglutide ~15% average weight loss.
• Jastreboff AM, et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM, 387(3):205-216. — SURMOUNT-1: tirzepatide ~20-22% average weight loss.